The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder
Latest Information Update: 03 Sep 2024
At a glance
- Drugs Psilocybin (Primary)
- Indications Post-traumatic stress disorders
- Focus Adverse reactions
- Sponsors COMPASS Pathways
- 29 Aug 2024 Status changed from active, no longer recruiting to completed.
- 08 May 2024 Results presented in the COMPASS Pathways Media Release
- 08 May 2024 According to a COMPASS Pathways media release, full results of this study for publication and potential presentation will be shared at an upcoming medical conference